Completed PHASE2 INTERVENTIONAL 2-arm NCT00806481

Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease

Does Phosphate Binding With Sevelamer Carbonate Improve Cardiovascular Structure and Function in Patients With Early Chronic Kidney Disease?

Sponsor: Genzyme, a Sanofi Company

Conditions Cardiovascular Diseases Kidney Failure, Chronic

Interventions Placebo Sevelamer carbonate

Updated 5 times since 2017 Last updated: Nov 22, 2011 Started: Feb 28, 2009 Primary completion: Oct 31, 2011 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cardiovascular Diseases and Kidney Failure, Chronic and is currently completed. Genzyme, a Sanofi Company leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genzyme, a Sanofi Company
University Hospital Birmingham NHS Foundation Trust

Data source: University Hospital Birmingham NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United Kingdom